Company Filing History:
1 out of 74 
1 out of 125 
1 out of 144 Years Active: 2017
Title: The Innovative Contributions of Hai-Jing Zhong
Introduction
Hai-Jing Zhong is a prominent inventor based in Macau, CN. He has made significant contributions to the field of cancer research, particularly through his innovative work on protein-protein interaction inhibitors. His research focuses on developing effective anticancer agents that target specific proteins involved in cancer progression.
Latest Patents
Hai-Jing Zhong holds a patent for an "Iridium(III)-based irreversible protein-protein interaction inhibitor of BRD4 as a potent anticancer agent." This invention highlights the potential of Iridium(III) complexes as irreversible inhibitors of Bromodomain-containing protein 4 (BRD4), which has emerged as an attractive target for anticancer therapy. The complex 1a formula is particularly noteworthy for its effectiveness in this area. He has 1 patent to his name.
Career Highlights
Throughout his career, Hai-Jing Zhong has worked at esteemed institutions such as the University of Macau and Hong Kong Baptist University. His research has contributed to advancing the understanding of epigenetic targets in cancer therapy, showcasing his commitment to improving treatment options for patients.
Collaborations
Hai-Jing Zhong has collaborated with notable colleagues, including Chung-Hang Leung and Dik-Lung Ma. These partnerships have further enriched his research and expanded the impact of his work in the scientific community.
Conclusion
Hai-Jing Zhong's innovative contributions to cancer research through his patent on Iridium(III) complexes demonstrate his dedication to finding effective treatments for cancer. His work continues to inspire advancements in the field of oncology.